ES2072875T3 - Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina. - Google Patents

Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina.

Info

Publication number
ES2072875T3
ES2072875T3 ES89112463T ES89112463T ES2072875T3 ES 2072875 T3 ES2072875 T3 ES 2072875T3 ES 89112463 T ES89112463 T ES 89112463T ES 89112463 T ES89112463 T ES 89112463T ES 2072875 T3 ES2072875 T3 ES 2072875T3
Authority
ES
Spain
Prior art keywords
treatment
vip
male impotence
conjugates
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89112463T
Other languages
English (en)
Inventor
Illana Gozes
Matityahu Fridkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2072875T3 publication Critical patent/ES2072875T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PRESENTAN COMPOSICIONES FARMACEUTICAS PARA LA APLICACION TRANSDERMICA TOPICA PARA EL TRATAMIENTO DE LA IMPOTENCIA MASCULINA Y COMPOSICIONES PARA EL TRATAMIENTO DEL ASMA Y LA HIPERTENSION. LOS INGREDIENTES ACTIVOS DE TALES COMPOSICIONES SON SELECCIONADOS ENTRE EL PEPTIDO INSTESTINAL VASOACTIVO (VIP) DERIVADAS EFECTIVOS DEL MISMO Y FRAGMENTO EFECTIVOS DEL MISMO. EN LAS COMPOSICIONES PARA EL TRATAMIENTO DE LA IMPOTENCIA MASCULINA ES USADO UN CONJUGADO TRANSDERMICAMENTE EFECTIVO DEL VIP. SUS DERIVADOS O FRAGMENTOS ACOPLADOS A UNA PARTE HIDROFOBICA.
ES89112463T 1988-07-08 1989-07-07 Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina. Expired - Lifetime ES2072875T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL8705588A IL87055A (en) 1988-07-08 1988-07-08 Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
ES2072875T3 true ES2072875T3 (es) 1995-08-01

Family

ID=11059032

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89112463T Expired - Lifetime ES2072875T3 (es) 1988-07-08 1989-07-07 Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina.

Country Status (7)

Country Link
US (1) US5147855A (es)
EP (1) EP0354992B1 (es)
JP (1) JP2682702B2 (es)
AT (1) ATE120091T1 (es)
DE (1) DE68921814T2 (es)
ES (1) ES2072875T3 (es)
IL (1) IL87055A (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
CA2352552C (en) * 1990-04-25 2008-12-02 Virgil A. Place Treatment of erectile dysfunction
DE69101187T2 (de) * 1990-06-26 1994-09-29 Sanwa Kagaku Kenkyusho Co VIP-Analogen und ihre Verwendung.
IL99924A (en) * 1991-10-31 1995-12-31 Yeda Res & Dev Derivatives of structurally modified vip and pharmaceutical compositions containing them
US5998368A (en) * 1991-10-31 1999-12-07 Yeda Research And Development Co. Ltd. Derivatives of structurally modified VIP and pharmaceutical compositions containing them
AU666914B2 (en) * 1991-12-10 1996-02-29 Tanox Biosystems, Inc. Cytokines with an unpaired cysteine residue and conjugates thereof
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5382392A (en) * 1993-02-05 1995-01-17 Alliedsignal Inc. Process for fabrication of carbon fiber-reinforced carbon composite material
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
EP0696919B1 (en) * 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
US5333621A (en) * 1993-05-28 1994-08-02 Eric Denzer Condom with transdermal vasodilator
IL118003A0 (en) * 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
AU742787B2 (en) 1997-07-09 2002-01-10 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
US6103765A (en) * 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
EP1409519A1 (en) * 2000-07-31 2004-04-21 Dabur Research Foundation Lipid-peptide conjugates for treatment of cancer
US6828304B1 (en) 2000-07-31 2004-12-07 Dabur Research Foundation Peptides for treatment of cancer
WO2002043746A2 (en) * 2000-11-28 2002-06-06 Mondobiotech Sa Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
ES2779992T3 (es) 2005-12-20 2020-08-21 Univ Duke Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
CA2804755C (en) 2009-08-14 2018-06-05 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
CA2947982C (en) 2014-05-08 2022-11-29 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
CN114652817A (zh) 2015-02-09 2022-06-24 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879371A (en) * 1971-09-17 1975-04-22 Sami I Said Isolation of vasoactive intestinal peptide
FR2308266A1 (fr) * 1975-04-18 1976-11-12 Telecommunications Sa Procede de transmission dans des reseaux de connexion temporels a grande capacite
DE3064888D1 (en) * 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
JPS56128721A (en) * 1980-03-12 1981-10-08 Eisai Co Ltd Antiallergic agent
US4605641A (en) * 1984-10-09 1986-08-12 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
GB8427651D0 (en) * 1984-11-01 1984-12-05 Beecham Group Plc Compounds
JPS61118399A (ja) * 1984-11-14 1986-06-05 Otsuka Pharmaceut Co Ltd ペプチドホルモンの製造法
GB8525852D0 (en) * 1985-10-19 1985-11-20 Beecham Group Plc Compounds
JPS62135407A (ja) * 1985-12-10 1987-06-18 Meiji Seika Kaisha Ltd 育毛剤
JPS62246595A (ja) * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
SE8702520D0 (sv) * 1987-06-16 1987-06-16 Kabigen Ab Mammal intestine hormone precursor
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides

Also Published As

Publication number Publication date
IL87055A0 (en) 1988-12-30
EP0354992A2 (en) 1990-02-21
JP2682702B2 (ja) 1997-11-26
DE68921814D1 (de) 1995-04-27
JPH0276821A (ja) 1990-03-16
US5147855A (en) 1992-09-15
IL87055A (en) 1994-06-24
ATE120091T1 (de) 1995-04-15
DE68921814T2 (de) 1995-09-28
EP0354992B1 (en) 1995-03-22
EP0354992A3 (en) 1991-01-16

Similar Documents

Publication Publication Date Title
ES2072875T3 (es) Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina.
EP0206291A3 (en) Sprayable pharmaceutical preparation for topical application
ATE92080T1 (de) Isolierung und strukturbestimmung des zytostatischen linearen depsipeptids dolastatin 15.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
YU46978B (sh) Postupak za dobijanje preparata za nazalnu upotrebu
BR9711447A (pt) Uso de glp-1 an logos no tratamento de enfarte de mioc rdio
IT1224795B (it) Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
HK1000283A1 (en) New derivatives of non-steroidal anti-inflammatory anaggesic and/or antipyretic substances their use and pharmaceutical formulations containg them
EP0177342A3 (en) Oral formulation of therapeutic proteins
DE69026269T2 (de) Bioadhäsive zusammensetzung und pflaster
IL78061A (en) Pharmaceutical compositions based on simethicone and guar gum for protection of the oesogastroduodenal mucous membrane
ES2061828T3 (es) Composiciones antiirritantes y desensibilizadoras y metodos para su uso.
EP0230264A3 (en) Pharmaceutical composition for nasal application, process for its preparation and its use
NO970178L (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
ES2052922T3 (es) Nucleosidos terapeuticos.
MX9203405A (es) Compuestos activos para usarse en el tratamiento de tumores.
ES2016464A6 (es) Procedimiento para preparar derivados de 2', 5' -oligoadenilato.
FI884240A (fi) Menetelmä paikalliseen käyttöön tarkoitetun farmaseuttisen valmisteen valmistamiseksi
IT8748117A0 (it) Derivati di glicina quali agenti preventivi e terapeutici per le complicanze diabetiche
DK68388D0 (da) Anvendelse af oxochinazolinderivater til fremstilling af laegemidler til behandling af hyperurikaemi
EG17992A (en) Preparation of a medicament for arthritis and theumatism
PT89742A (pt) Processo de preparacao de 24r-cimnol e de suas composicoes farmaceuticas
MX9303985A (es) Nucleosidos terapeuticos.
KR870005642A (ko) 디플루니살과 트로메타민의 혼합물

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 354992

Country of ref document: ES